Phase 3 Readout~month

Phase 3 Topline: Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safet

Indication
Hypogonadism, Male

Other upcoming events for HALO

Patent ExpiryPatent/Exclusivity Expiry: TLANDO

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safet — HALO Phase 3 Readout | BioSniper